Skip to main content
Top
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4)

Authors: Hilmar Quentmeier, Sonja Eberth, Julia Romani, Herbert A Weich, Margarete Zaborski, Hans G Drexler

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Vascular Endothelial Growth Factors (VEGFs) and their receptors (VEGF-Rs) are important regulators for angiogenesis and lymphangiogenesis. VEGFs and VEGF-Rs are not only expressed on endothelial cells but also on various subtypes of solid tumors and leukemias contributing to the growth of the malignant cells. This study was performed to examine whether VEGF-R2 (KDR) and VEGF-R3 (FLT4) are regulated by DNA methylation.

Methods

Real-time (RT) PCR analysis was performed to quantify KDR and FLT4 expression in some ninety leukemia/lymphoma cell lines, human umbilical vein endothelial cells (HUVECs) and dermal microvascular endothelial cells (HDMECs). Western blot analyses and flow cytometric analyses confirmed results at the protein level. After bisulfite conversion of DNA we determined the methylation status of KDR and FLT4 by DNA sequencing and by methylation specific PCR (MSP). Western blot analyses were performed to examine the effect of VEGF-C on p42/44 MAPK activation.

Results

Expression of KDR and FLT4 was observed in cell lines from various leukemic entities, but not in lymphoma cell lines: 16% (10/62) of the leukemia cell lines expressed KDR, 42% (27/65) were FLT4 positive. None of thirty cell lines representing six lymphoma subtypes showed more than marginal expression of KDR or FLT4. Western blot analyses confirmed KDR and FLT4 protein expression in HDMECs, HUVECs and in cell lines with high VEGF-R mRNA levels. Mature VEGF-C induced p42/44 MAPK activation in the KDR- /FLT4+ cell line OCI-AML1 verifying the model character of this cell line for VEGF-C signal transduction studies. Bisulfite sequencing and MSP revealed that GpG islands in the promoter regions of KDR and FLT4 were unmethylated in HUVECs, HDMECs and KDR + and FLT4 + cell lines, whereas methylated cell lines did not express these genes. In hypermethylated cell lines, KDR and FLT4 were re-inducible by treatment with the DNA demethylating agent 5-Aza-2'deoxycytidine, confirming epigenetic regulation of both genes.

Conclusions

Our data show that VEGF-Rs KDR and FLT4 are silenced by DNA methylation. However, if the promoters are unmethylated, other factors (e.g. transactivation factors) determine the extent of KDR and FLT4 expression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Larrivée B, Karsan A: Signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med. 2000, 5: 447-456.PubMed Larrivée B, Karsan A: Signaling pathways induced by vascular endothelial growth factor (review). Int J Mol Med. 2000, 5: 447-456.PubMed
2.
go back to reference Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR: Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010, 1806: 108-121.PubMedPubMedCentral Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR: Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010, 1806: 108-121.PubMedPubMedCentral
3.
go back to reference de Jong JS, van Diest PV, van der Valk P, Baak JPA: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol. 1998, 184: 44-52. 10.1002/(SICI)1096-9896(199801)184:1<44::AID-PATH984>3.0.CO;2-H.CrossRefPubMed de Jong JS, van Diest PV, van der Valk P, Baak JPA: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol. 1998, 184: 44-52. 10.1002/(SICI)1096-9896(199801)184:1<44::AID-PATH984>3.0.CO;2-H.CrossRefPubMed
4.
go back to reference Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Nat Cancer Inst. 1995, 87: 506-516. 10.1093/jnci/87.7.506.CrossRefPubMed Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Nat Cancer Inst. 1995, 87: 506-516. 10.1093/jnci/87.7.506.CrossRefPubMed
5.
go back to reference Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999, 54: 567-572. 10.1016/S0090-4295(99)00156-9.CrossRefPubMed Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999, 54: 567-572. 10.1016/S0090-4295(99)00156-9.CrossRefPubMed
6.
go back to reference Takahama M, Tsutsumi M, Tsujiuchi T, Kido A, Sakitani H, Iki K, Taniguchi S, Kitamura S, Konishi Y: Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinogenesis. 1999, 24: 287-293. 10.1002/(SICI)1098-2744(199904)24:4<287::AID-MC6>3.0.CO;2-T.CrossRef Takahama M, Tsutsumi M, Tsujiuchi T, Kido A, Sakitani H, Iki K, Taniguchi S, Kitamura S, Konishi Y: Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinogenesis. 1999, 24: 287-293. 10.1002/(SICI)1098-2744(199904)24:4<287::AID-MC6>3.0.CO;2-T.CrossRef
7.
go back to reference Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MAS, Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000, 106: 511-521. 10.1172/JCI8978.CrossRefPubMedPubMedCentral Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MAS, Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000, 106: 511-521. 10.1172/JCI8978.CrossRefPubMedPubMedCentral
8.
go back to reference Pazgal I, Boycov O, Shpilberg O, Okon E, Bairey O: Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymph. 2007, 48: 2213-2220. 10.1080/10428190701632822.CrossRef Pazgal I, Boycov O, Shpilberg O, Okon E, Bairey O: Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymph. 2007, 48: 2213-2220. 10.1080/10428190701632822.CrossRef
9.
go back to reference Kivivuori SM, Siitonen S, Porkka K, Vettenranta K, Alitalo R, Saarinen-Pihkala U: Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer. 2007, 48: 387-392. 10.1002/pbc.20857.CrossRefPubMed Kivivuori SM, Siitonen S, Porkka K, Vettenranta K, Alitalo R, Saarinen-Pihkala U: Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer. 2007, 48: 387-392. 10.1002/pbc.20857.CrossRefPubMed
10.
go back to reference Fielder W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, Hossfeld DK: Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997, 11: 1234-1237. 10.1038/sj.leu.2400722.CrossRefPubMed Fielder W, Graeven U, Ergün S, Verago S, Kilic N, Stockschläder M, Hossfeld DK: Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997, 11: 1234-1237. 10.1038/sj.leu.2400722.CrossRefPubMed
11.
go back to reference Joergensen JM, Soerensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ, Tainola T, Soerensen AB, Pedersen FS, D'Amore F: Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymph. 2009, 50: 1647-1660. 10.1080/10428190903156729.CrossRef Joergensen JM, Soerensen FB, Bendix K, Nielsen JL, Funder A, Karkkainen MJ, Tainola T, Soerensen AB, Pedersen FS, D'Amore F: Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas. Leuk Lymph. 2009, 50: 1647-1660. 10.1080/10428190903156729.CrossRef
12.
go back to reference Dias S, Choy M, Alitalo K, Rafii S: Vascular endothelial factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002, 99: 2179-2184. 10.1182/blood.V99.6.2179.CrossRefPubMed Dias S, Choy M, Alitalo K, Rafii S: Vascular endothelial factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002, 99: 2179-2184. 10.1182/blood.V99.6.2179.CrossRefPubMed
13.
go back to reference Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S: Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-κB and Prox1. Blood. 2010, 115: 418-429. 10.1182/blood-2008-12-196840.CrossRefPubMedPubMedCentral Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S: Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-κB and Prox1. Blood. 2010, 115: 418-429. 10.1182/blood-2008-12-196840.CrossRefPubMedPubMedCentral
14.
go back to reference Kim JY, Hwang JH, Zhou W, Shin J, Noh SM, Song IS, Kim JY, Lee SH, Kim J: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VDGF activation. Epigenetics. 2009, 4: 313-321. 10.4161/epi.4.5.9160.CrossRefPubMed Kim JY, Hwang JH, Zhou W, Shin J, Noh SM, Song IS, Kim JY, Lee SH, Kim J: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VDGF activation. Epigenetics. 2009, 4: 313-321. 10.4161/epi.4.5.9160.CrossRefPubMed
15.
go back to reference Kiec-Wilk B, Razny U, Mathers JC, Dembinska-Kiec A: DNA methylation, induced by beta-carotene and arachidonic acid, plays a regulatory role in the pro-angiogenic VEGF-receptor (KDR) gene expression in endothelial cells. J Physiol Pharmacol. 2009, 60: 49-53.PubMed Kiec-Wilk B, Razny U, Mathers JC, Dembinska-Kiec A: DNA methylation, induced by beta-carotene and arachidonic acid, plays a regulatory role in the pro-angiogenic VEGF-receptor (KDR) gene expression in endothelial cells. J Physiol Pharmacol. 2009, 60: 49-53.PubMed
16.
go back to reference Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. 2010, Braunschweig, 2 Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. 2010, Braunschweig, 2
17.
go back to reference Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, MacLeod RAF, Drexler HG: SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. 2009, 2: 3-10.1186/1756-8722-2-3.CrossRefPubMedPubMedCentral Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, MacLeod RAF, Drexler HG: SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol. 2009, 2: 3-10.1186/1756-8722-2-3.CrossRefPubMedPubMedCentral
18.
go back to reference Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MAS, Rafii S: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA. 2001, 98: 10857-10862. 10.1073/pnas.191117498.CrossRefPubMedPubMedCentral Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MAS, Rafii S: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA. 2001, 98: 10857-10862. 10.1073/pnas.191117498.CrossRefPubMedPubMedCentral
19.
go back to reference Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001, 97: 1427-1434. 10.1182/blood.V97.5.1427.CrossRefPubMed Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001, 97: 1427-1434. 10.1182/blood.V97.5.1427.CrossRefPubMed
20.
go back to reference Drexler HG, Zaborski M, Quentmeier H: Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia. 1997, 11: 701-708. 10.1038/sj.leu.2400633.CrossRefPubMed Drexler HG, Zaborski M, Quentmeier H: Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia. 1997, 11: 701-708. 10.1038/sj.leu.2400633.CrossRefPubMed
21.
go back to reference Salameh A, Glavagni F, Bardelli M, Bussolino F, Oliviero S: Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. 2005, 106: 3423-3431. 10.1182/blood-2005-04-1388.CrossRefPubMed Salameh A, Glavagni F, Bardelli M, Bussolino F, Oliviero S: Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. 2005, 106: 3423-3431. 10.1182/blood-2005-04-1388.CrossRefPubMed
22.
go back to reference Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML: Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis. 2009, 30: 2005-2013. 10.1093/carcin/bgp244.CrossRefPubMed Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML: Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis. 2009, 30: 2005-2013. 10.1093/carcin/bgp244.CrossRefPubMed
23.
go back to reference Santos-Rosa H, Caldas C: Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer. 2005, 41: 2381-2402. 10.1016/j.ejca.2005.08.010.CrossRefPubMed Santos-Rosa H, Caldas C: Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer. 2005, 41: 2381-2402. 10.1016/j.ejca.2005.08.010.CrossRefPubMed
24.
go back to reference Kerppola TK: Polycomb group complexes-many combinations, many functions. Trend Cell Biol. 2009, 19: 692-704. 10.1016/j.tcb.2009.10.001.CrossRef Kerppola TK: Polycomb group complexes-many combinations, many functions. Trend Cell Biol. 2009, 19: 692-704. 10.1016/j.tcb.2009.10.001.CrossRef
25.
go back to reference Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.CrossRefPubMed Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.CrossRefPubMed
26.
go back to reference Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16: 6-21. 10.1101/gad.947102.CrossRefPubMed Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16: 6-21. 10.1101/gad.947102.CrossRefPubMed
27.
go back to reference Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E: Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem. 1995, 39: 23111-23118.CrossRef Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E: Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem. 1995, 39: 23111-23118.CrossRef
28.
go back to reference Morr M, Takeuchi O, Akira S, Simon MM, Mühlradt PF: Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol. 2002, 32: 3337-3347.CrossRefPubMed Morr M, Takeuchi O, Akira S, Simon MM, Mühlradt PF: Differential recognition of structural details of bacterial lipopeptides by toll-like receptors. Eur J Immunol. 2002, 32: 3337-3347.CrossRefPubMed
29.
go back to reference Sacht G, Märten A, Deiters U, Süßmuth R, Jung G, Wingender E, Mühlradt PF: Activation of nuclear factor-κB in macrophages by mycoplasmal lipopeptides. Eur J Immunol. 1998, 28: 4207-4212. 10.1002/(SICI)1521-4141(199812)28:12<4207::AID-IMMU4207>3.0.CO;2-R.CrossRefPubMed Sacht G, Märten A, Deiters U, Süßmuth R, Jung G, Wingender E, Mühlradt PF: Activation of nuclear factor-κB in macrophages by mycoplasmal lipopeptides. Eur J Immunol. 1998, 28: 4207-4212. 10.1002/(SICI)1521-4141(199812)28:12<4207::AID-IMMU4207>3.0.CO;2-R.CrossRefPubMed
30.
go back to reference Kaufmann A, Mühlradt PF, Gemsa D, Sprengler H: Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun. 1999, 67: 6303-6308.PubMedPubMedCentral Kaufmann A, Mühlradt PF, Gemsa D, Sprengler H: Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun. 1999, 67: 6303-6308.PubMedPubMedCentral
Metadata
Title
DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4)
Authors
Hilmar Quentmeier
Sonja Eberth
Julia Romani
Herbert A Weich
Margarete Zaborski
Hans G Drexler
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-19

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine